SORT1 and glioblastoma: The Kaplan–Meier analysis showed that the 2-year survival rates of sortilin-low (n = 266) and sortilin-high (n = 219) GBM patients were 26% and 17%, respectively, and the 5-year survival rates were 9% and 1%, respectively (Fig. 1c).